Alto Neuroscience, Inc. financial data

Symbol
ANRO on NYSE
Location
650 Castro Street, Suite 450, Mountain View, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.81K % +0.65%
Debt-to-equity 24.5 % +46.9%
Return On Equity -47.4 % +3.86%
Return On Assets -38.1 % -13.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.1M shares +15.2%
Common Stock, Shares, Outstanding 27.2M shares +0.74%
Entity Public Float 267M USD
Weighted Average Number of Shares Outstanding, Basic 27.1M shares +0.54%
Weighted Average Number of Shares Outstanding, Diluted 27.1M shares +0.54%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 44.4M USD -3.09%
General and Administrative Expense 21.9M USD +24.8%
Operating Income (Loss) -66.3M USD -4.62%
Nonoperating Income (Expense) 4.05M USD -31.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -62.3M USD -8.37%
Earnings Per Share, Basic -2 USD/shares +54.7%
Earnings Per Share, Diluted -2 USD/shares +54.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 138M USD -24.2%
Other Assets, Current 23K USD -84.7%
Assets, Current 139M USD -24%
Property, Plant and Equipment, Net 2.03M USD -13.8%
Operating Lease, Right-of-Use Asset 4.46M USD -14.7%
Assets 147M USD -23.3%
Accounts Payable, Current 2.06M USD -8.57%
Employee-related Liabilities, Current 3.21M USD -17.2%
Accrued Liabilities, Current 6.99M USD -15.2%
Liabilities, Current 9.05M USD -35.5%
Operating Lease, Liability, Noncurrent 3.97M USD -14.1%
Liabilities 35.4M USD +33.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 14K USD
Retained Earnings (Accumulated Deficit) -185M USD -50.5%
Stockholders' Equity Attributable to Parent 112M USD -32.4%
Liabilities and Equity 147M USD -23.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.6M USD -50.7%
Net Cash Provided by (Used in) Financing Activities 9.13M USD -93.2%
Net Cash Provided by (Used in) Investing Activities -24K USD +89.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 27.2M shares +0.74%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.48M USD -106%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 138M USD -24.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 311K USD +25.4%
Deferred Tax Assets, Valuation Allowance 37.4M USD +62.5%
Deferred Tax Assets, Gross 39.4M USD +69.9%
Operating Lease, Liability 5.39M USD +4209%
Depreciation 200K USD 0%
Payments to Acquire Property, Plant, and Equipment 24K USD -89.3%
Lessee, Operating Lease, Liability, to be Paid 7.07M USD
Operating Lease, Liability, Current 1.12M USD +56.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.22M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 917K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +112%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.68M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.46M USD
Deferred Tax Assets, Operating Loss Carryforwards 12.1M USD +14.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.5M USD
Operating Lease, Payments 0 USD
Additional Paid in Capital 297M USD +3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 576K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 1.97M USD +1246%
Share-based Payment Arrangement, Expense 7.73M USD +15.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares